SCHEMBL29435642

SCHEMBL29435642

CN(C(=O)OC(C)(C)C)c1cnc(N)c(C(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNA1C Q13936 1/20 0.38
PIK3CA P42336 7/20 0.36
BRD4 O60885 1/20 0.36
MAP3K12 Q12852 2/20 0.36
PAX8 Q06710 1/20 0.36
BACE1 P56817 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP3A4 P08684 1/20 0.34
RXRA P19793 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
DDR1 Q08345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29435635 0.84 MEN1 (0.42) CACNA1GCACNA1BCACNA1CBRD4PAX8
SCHEMBL24549808 0.83 BRD4 (0.39) BRD4PAX8BACE1
SCHEMBL29435629 0.82 NOS3 (0.39) BRD4PAX8BACE1PIK3CDLIPE
SCHEMBL22583357 0.82 PIK3CA (0.40) PIK3CAMAP3K12MEN1KMT2ACYP3A4
SCHEMBL22583490 0.80 CACNA1G (0.34) CACNA1GCACNA1BCACNA1CBRD4PAX8
SCHEMBL22583253 0.78 CACNA1G (0.34) CACNA1GCACNA1BCACNA1CBRD4PAX8
SCHEMBL29435707 0.78 CACNA1G (0.34) CACNA1GCACNA1BCACNA1CBRD4PAX8
SCHEMBL22583491 0.77 LMNA (0.35) CACNA1GCACNA1BCACNA1CBRD4PAX8
SCHEMBL22583020 0.76 ALDH1A1 (0.38) CACNA1GCACNA1BCACNA1CMEN1KMT2A
SCHEMBL22583431 0.76 BACE1 (0.34) CACNA1GCACNA1BCACNA1CBRD4PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES SIGNAL PHARMACEUTICALS, LLC 2025-09-04 US disclosed
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CELGENE CORPORATION (US) 2025-06-24 US disclosed
US-11505548-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CELGENE CORPORATION (US) 2022-11-22 US disclosed
EP-3959207-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2022-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, HAX1, HRH4 CACNA1G 3762/4885CACNA1B 3782/4885CACNA1C 3929/4885
US-11505548-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CYP8B1, HAX1, HRH4 CACNA1G 3762/4885CACNA1B 3782/4885CACNA1C 3929/4885
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CYP8B1, HAX1, HRH4 CACNA1G 3762/4885CACNA1B 3782/4885CACNA1C 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.